A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The company is a medical dictation solution used by medical practitioners
Support from DFC will help produce one billion vaccine doses by the end of 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
